Insulet raised its 2026 revenue growth forecast to a range of 21% to 23% following a first-quarter earnings beat on Wednesday. The medical device maker previously projected growth between 20% and 22% as demand for its tubeless insulin pumps accelerates. This revision signals successful capture of the expanding diabetes technology market.

Omnipod Demand Drives Revenue Surge